AXSM241220P45000
- 1.25
- 0.000.00%
Axsome Therapeutics Newsroom
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $175
Analysts Are Bullish on Top Healthcare Stocks: Axsome Therapeutics (AXSM), Madrigal Pharmaceuticals (MDGL)
Axsome Therapeutics (AXSM) Gets a Buy From RBC Capital
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Truist Financial Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Positive Outlook on Axsome Therapeutics Driven by Promising Clinical Trial Results and Long-term Growth Potential
Axsome Therapeutics Reveals AXS-12 Meets Primary Endpoint In ENCORE Long-Term Phase 3 Trial In Narcolepsy
Express News | Axsome Therapeutics Inc - Axs-12 Improves Cognition Compared to Placebo
Express News | Axsome Therapeutics Announces Axs-12 Achieves Primary Endpoint in Encore Long-Term Phase 3 Trial in Narcolepsy
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
Getting In Cheap On Axsome Therapeutics, Inc. (NASDAQ:AXSM) Might Be Difficult
Axsome Therapeutics Analyst Ratings
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $180
Cantor Fitzgerald Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $121
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
Ladenburg Thalmann Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $175
A Quick Look at Today's Ratings for Axsome Therapeutics(AXSM.US), With a Forecast Between $116 to $150
RBC Lifts Price Target on Axsome Therapeutics to $132 From $131, Keeps Outperform Rating